Clinical Impact of Primary Tumor Location and<i>RAS, BRAF</i>V600E, and<i>PIK3CA</i>Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer

Abstract

Additional analysis of RAS and BRAF mutations could contribute to the selection of patients who are likely to benefit from third-line EGFR inhibitors, regardless of primary tumor location.